Abstract
Background Intermittent hypoxemia (IH) may influence retinopathy of prematurity (ROP) development in preterm infants, however, previous studies had mixed results. This study aims to assess the influence and evaluate the predictive ability of IH measures on Type 1 ROP, a stage beyond which ROP treatment is indicated.
Methods IH was quantified by continuously monitoring oxygen saturation (SpO2) using high-resolution pulse oximeters during the first 10 weeks of life. Statistical analyses assessed the relationship and predictive ability of weekly and cumulative IH variables for Type 1 ROP development.
Results Univariate analyses suggested that IH measures are greater in infants with Type 1 ROP and are predictive of Type 1 ROP development. Multivariable logistic regression analyses revealed that cumulative IH of longer duration during certain postnatal periods are associated with Type 1 ROP development after adjusting for gestational age (GA) or birth weight (BW). Although area under the curve (AUC) analyses revealed added predictivity of cumulative IH variables above GA or BW, these increments in AUC were not statistically significant.
Conclusions The duration of IH events was associated with Type 1 ROP development. Interventions for reducing the duration of IH events may potentially improve ROP outcomes.
This study investigates the impact of IH on the development of Type 1 ROP in preterm infants.
Univariate analyses revealed that IH measures are greater in infants with Type 1 ROP and are predictive of Type 1 ROP development.
Multivariable logistic regression analyses revealed that cumulative IH events of longer duration are associated with Type 1 ROP development after adjusting for GA or BW.
Interventions for reducing the duration of IH events during critical postnatal periods may potentially improve ROP outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
G.Y. was supported by National Institutes of Health (NIH) R01-EB028792, R01-HD101508, R21-HD091118, R21-NS114771, R41-NS122722, R56-NS117587, R01-AG062480. E.G.A was supported by the National Center for Advancing Translational Sciences (UL1TR001998), NIH K23HD109471, and the University of Kentucky College of Medicine Deans Office. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or University of Kentucky.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Kentucky's Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest: The authors declare no conflict of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
